Patient:innen sollten über die Nutzen-Risiko-Abwägung zu ihrer JAKi-Therapie informiert werden, besonders bei ausgeprägterem Risikoprofil
- 28 May 2026
- journal article
- Published by Springer Nature in Zeitschrift für Rheumatologie
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Risiko inzidenter Malignome nach Exposition gegenüber Januskinase-Inhibitoren und biologischen DMARDZeitschrift für Rheumatologie, 2025
- Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT registerAnnals of the Rheumatic Diseases, 2025
- Cardiovascular, cancer, and infection risks of Janus kinase inhibitors in rheumatoid arthritis and ulcerative colitis: A nationwide cohort studyJournal of Internal Medicine, 2025
- The application of lag times in cancer pharmacoepidemiology: a narrative reviewAnnals of Epidemiology, 2023
- Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort studyRheumatology, 2023
- Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort studyAnnals of the Rheumatic Diseases, 2023
- Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trialAnnals of the Rheumatic Diseases, 2022
- Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid ArthritisNew England Journal of Medicine, 2022
- RMD commentary, JAK kinase inhibitors: a preferred alternative to TNF inhibitors?RMD Open, 2021